2.08

8.19% -0.18

Cabaletta Bio Inc (CABA)

Overview News Price History Option Chain Financials Why CABA Down? Discussions Forecast

Cabaletta Bio Inc stock is traded at $2.08, with a volume of 931.26K. It is down -8.19% in the last 24 hours and down -54.09% over the past month. Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) has the potential to be applied across a broad range of autoimmune diseases.

Previous Close:

$2.26

Open:

$2.28

24h Volume:

931.26K

Relative Volume:

0.92

Market Cap:

$117.73M

Revenue:

Net Income/Loss:

$-67.68M

P/E Ratio:

-1.2023

EPS:

-1.73

Net Cash Flow:

$-54.24M

1W Performance:

-45.11%

1M Performance:

-54.09%

6M Performance:

-82.98%

1Y Performance:

-88.22%

1-Day Range:

$1.935

$2.30

1-Week Range:

$1.935

$3.84

52-Week Range:

$1.935

$26.35

Cabaletta Bio Inc Stock (CABA) Company Profile

Name

Cabaletta Bio Inc

Sector

Healthcare (1195)

Industry

Biotechnology (683)

Phone

(267) 759-3100

Address

2929 ARCH STREET, PHILADELPHIA, PA

Employee

154

Twitter

@CabalettaBio

Next Earnings Date

2024-11-07

Latest SEC Filings

CABA's Discussions on Twitter

Compare CABA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CABA	2.09	117.73M	0	-67.68M	-54.24M	-1.73
VRTX	445.82	115.74B	10.63B	-479.80M	-1.35B	13.33
REGN	741.34	81.65B	13.85B	4.65B	3.32B	35.06
ARGX	589.04	34.86B	1.86B	-40.29M	-1.28B	-4.16
ALNY	248.89	32.09B	2.09B	-332.26M	16.06M	-4.14
BNTX	102.89	24.49B	3.30B	-501.07M	1.03B	11.54

Cabaletta Bio Inc Stock (CABA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-05-23	Initiated	Citigroup	Buy
Jul-18-23	Initiated	Guggenheim	Buy
Jan-27-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Aug-30-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Dec-08-21	Initiated	Wells Fargo	Overweight
Oct-19-21	Resumed	Morgan Stanley	Overweight
Jun-30-21	Initiated	Mizuho	Buy
Jan-08-21	Initiated	Chardan Capital Markets	Buy
Oct-13-20	Initiated	H.C. Wainwright	Buy
Nov-19-19	Initiated	Cowen	Outperform
Nov-19-19	Initiated	Evercore ISI	Outperform
Nov-19-19	Initiated	Morgan Stanley	Overweight

View All

Cabaletta Bio Inc Stock (CABA) Latest News

03:00 AM

Cabaletta Bio Unveils Promising Data on CABA-201 at ACR Convergence 2024 - MyChesCo

03:00 AM

Nov 20, 2024

Cabaletta Bio to Spotlight Groundbreaking Cell Therapies at Guggenheim’s Healthcare Innovation Conference! - MSN

Nov 20, 2024

Cabaletta Bio Reports Q3 2024 Financial Results and Clinical Trial Advancements - MSN

Nov 20, 2024

Nov 19, 2024

Cabaletta Bio shares retain Buy rating as H.C. Wainwright sees robust treatment effect - Investing.com

Nov 19, 2024

Nov 18, 2024

Cabaletta Bio Reports Q3 2024 Financial Results - TipRanks

Nov 18, 2024

Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024 - The Manila Times

Nov 18, 2024

Cabaletta reports promising autoimmune therapy results - Investing.com

Nov 18, 2024

Cabaletta Bio’s (CABA) Buy Rating Reiterated at HC Wainwright - Defense World

Nov 18, 2024

Nov 15, 2024

Cabaletta Bio (NASDAQ:CABA) Given New $12.00 Price Target at Wells Fargo & Company - MarketBeat

Nov 15, 2024

Cabaletta Bio stock hits 52-week low at $3.47 amid market challenges - Investing.com UK

Nov 15, 2024

Cabaletta Bio (NASDAQ:CABA) Earns "Buy" Rating from HC Wainwright - MarketBeat

Nov 15, 2024